ATE355374T1 - Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen - Google Patents
Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungenInfo
- Publication number
- ATE355374T1 ATE355374T1 AT01995259T AT01995259T ATE355374T1 AT E355374 T1 ATE355374 T1 AT E355374T1 AT 01995259 T AT01995259 T AT 01995259T AT 01995259 T AT01995259 T AT 01995259T AT E355374 T1 ATE355374 T1 AT E355374T1
- Authority
- AT
- Austria
- Prior art keywords
- therapeutic agents
- methods
- treatment
- amyloidogenic diseases
- treating
- Prior art date
Links
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title abstract 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title abstract 3
- 230000003942 amyloidogenic effect Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25330200P | 2000-11-27 | 2000-11-27 | |
| US25019800P | 2000-11-29 | 2000-11-29 | |
| US25718600P | 2000-12-20 | 2000-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355374T1 true ATE355374T1 (de) | 2006-03-15 |
Family
ID=27400294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01995259T ATE355374T1 (de) | 2000-11-27 | 2001-11-27 | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20020133001A1 (de) |
| EP (1) | EP1346041B1 (de) |
| JP (1) | JP2004534511A (de) |
| AT (1) | ATE355374T1 (de) |
| AU (1) | AU2002225772A1 (de) |
| DE (1) | DE60126980T2 (de) |
| DK (1) | DK1346041T3 (de) |
| ES (1) | ES2283463T3 (de) |
| PT (1) | PT1346041E (de) |
| WO (1) | WO2002042462A2 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US20030082191A1 (en) * | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| EP1457500A1 (de) * | 2003-03-14 | 2004-09-15 | University of Zurich | Lösliche Prionen-Hybrid-Proteine und deren Verwendung zur Diagnose, Behandlung und Prevention von transmissibler spongiformer Encephalopathie |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| US20060069010A1 (en) * | 2003-10-17 | 2006-03-30 | Senicure Llc | Detoxification depot for Alzheimer's disease |
| WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
| ES2330951T3 (es) * | 2004-03-02 | 2009-12-17 | Cellectar, Inc. | Analogos de fosfolipido para el tratamiento de canceres. |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| GB2424886A (en) | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
| US20070092508A1 (en) * | 2005-10-21 | 2007-04-26 | Recombiant Technologies, Llc | Detoxification depot for Alzheimer's disease |
| JP5475994B2 (ja) | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
| KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| GB0605735D0 (en) * | 2006-03-22 | 2006-05-03 | Immunobiology Ltd | Composition and method for mediating an immune response |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| GB0615266D0 (en) * | 2006-08-01 | 2006-09-06 | Immunobiology Ltd | Composition and method for mediating an immune response |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| JP5554528B2 (ja) * | 2009-09-08 | 2014-07-23 | 国立大学法人 岡山大学 | 新規アミロイドβ凝集体結合性ペプチドおよび新規アミロイドβ凝集体結合性ペプチドを用いたアミロイド病の検査方法 |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
| DK2834643T3 (da) | 2012-04-05 | 2020-02-03 | Forschungszentrum Juelich Gmbh | Fremgangsmåde til behandling af blod, blodprodukter og organer |
| EP3572814A3 (de) * | 2012-04-05 | 2020-02-26 | Forschungszentrum Jülich GmbH | Polymere; enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung |
| DE102012108598A1 (de) * | 2012-09-14 | 2014-04-10 | Forschungszentrum Jülich GmbH | Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung |
| FR3012453B1 (fr) * | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| PL417159A1 (pl) * | 2016-05-11 | 2017-11-20 | Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego | Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera |
| IL302388A (en) | 2020-11-02 | 2023-06-01 | Attralus Inc | SAP FC fusion proteins and methods of use |
| IL308004A (en) * | 2021-05-05 | 2023-12-01 | Univ Tennessee Res Found | Peptide-fc fusions for treating amyloid disorders |
| CN113398253B (zh) * | 2021-05-14 | 2023-01-24 | 北京化工大学 | β2微球蛋白聚集抑制剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071517A (en) * | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
| US5635600A (en) * | 1986-07-07 | 1997-06-03 | Trustees Of Dartmouth College | Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5200178A (en) * | 1988-02-26 | 1993-04-06 | The General Hospital Corporation | Method for tumor detection |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5981194A (en) * | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| JPH11514333A (ja) * | 1995-03-14 | 1999-12-07 | プレーシス ファーマスーティカルズ インコーポレイテッド | アミロイドの凝集の調節剤 |
| US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US5786187A (en) * | 1995-09-21 | 1998-07-28 | The Research Foundation Of State University Of New York | Method for reducing neuronal degeneration associated with seizure |
| US6071493A (en) * | 1996-09-20 | 2000-06-06 | Baylor College Of Medicine | Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation |
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
-
2001
- 2001-11-27 US US09/996,357 patent/US20020133001A1/en not_active Abandoned
- 2001-11-27 AU AU2002225772A patent/AU2002225772A1/en not_active Abandoned
- 2001-11-27 EP EP01995259A patent/EP1346041B1/de not_active Expired - Lifetime
- 2001-11-27 AT AT01995259T patent/ATE355374T1/de not_active IP Right Cessation
- 2001-11-27 PT PT01995259T patent/PT1346041E/pt unknown
- 2001-11-27 DE DE60126980T patent/DE60126980T2/de not_active Expired - Fee Related
- 2001-11-27 JP JP2002545167A patent/JP2004534511A/ja active Pending
- 2001-11-27 DK DK01995259T patent/DK1346041T3/da active
- 2001-11-27 ES ES01995259T patent/ES2283463T3/es not_active Expired - Lifetime
- 2001-11-27 WO PCT/US2001/044581 patent/WO2002042462A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002042462A2 (en) | 2002-05-30 |
| EP1346041A2 (de) | 2003-09-24 |
| DK1346041T3 (da) | 2007-07-02 |
| US20020133001A1 (en) | 2002-09-19 |
| DE60126980T2 (de) | 2007-11-08 |
| PT1346041E (pt) | 2007-06-05 |
| AU2002225772A1 (en) | 2002-06-03 |
| WO2002042462A3 (en) | 2003-06-19 |
| EP1346041B1 (de) | 2007-02-28 |
| ES2283463T3 (es) | 2007-11-01 |
| JP2004534511A (ja) | 2004-11-18 |
| DE60126980D1 (de) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| CY1120977T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| ATE439833T1 (de) | Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten | |
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
| DE60219680D1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
| YU24603A (sh) | Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin | |
| ATE147978T1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
| ATE337790T1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| ATE245151T1 (de) | Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung | |
| DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1346041 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |